Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India.
J Clin Psychiatry. 2019 Apr 9;80(2):19f12838. doi: 10.4088/JCP.19f12838.
The oral route of administration is probably the least expensive and most convenient way to administer ketamine in indicated contexts in depressed patients. Because only 20%-25% of orally administered ketamine reaches systemic circulation, oral doses of about 2.0-2.5 mg/kg may need to be administered to achieve equivalence to intravenously administered ketamine. In case reports, case series, standard operating practice in ketamine facilities, and randomized controlled trials, oral ketamine has been administered through weight-based dosing and as fixed doses, and the dosing strategy has been one-size-fits-all or individualized through a dose discovery process. Administered doses have ranged from 0.25 to 7.0 mg/kg in weight-based dosing sessions and from 25 mg to 300 mg in fixed dosing sessions. This article reviews strategies for dosing with oral ketamine, dose discovery procedures, rates of dosing during a session, the frequency of dosing sessions and the duration of treatment, treatment in the clinic vs domiciliary treatment, adverse effects and risks, and safety issues. Finally, this article provides a detailed account of practices and experiences with oral ketamine so that readers may know what to expect when the treatment is orally administered. Whereas oral ketamine appears to be a safe and effective treatment and could make ketamine an accessible and affordable intervention in less privileged medical facilities, readers are warned that the literature on oral ketamine is thin and that there are many areas that need more investigation, especially matters related to pharmacokinetics, physiologic effects, abuse potential and strategies to mitigate illicit use, and adverse effects and efficacy relative to other routes of administration. Until studies of a sufficiently high quality become available, the use of oral ketamine to treat depression must be considered experimental.
口服途径可能是在有适应证的抑郁患者中给予氯胺酮最经济、最方便的方法。由于只有 20%-25%的口服氯胺酮能到达体循环,因此可能需要给予约 2.0-2.5mg/kg 的口服剂量,才能达到与静脉给予氯胺酮等效的效果。在病例报告、病例系列、氯胺酮治疗机构的标准操作实践和随机对照试验中,已经通过基于体重的剂量和固定剂量给予口服氯胺酮,并且剂量策略是一刀切或通过剂量发现过程进行个体化。基于体重的剂量方案中,给予的剂量范围为 0.25-7.0mg/kg,固定剂量方案中,给予的剂量范围为 25-300mg。本文综述了口服氯胺酮的剂量方案、剂量发现程序、单次剂量方案中的剂量率、剂量方案的频率和治疗持续时间、诊所治疗与家庭治疗、不良反应和风险以及安全问题。最后,本文详细介绍了口服氯胺酮的实践和经验,以便读者在给予该治疗时了解可能的预期。虽然口服氯胺酮似乎是一种安全有效的治疗方法,并且可以使氯胺酮在医疗条件较差的地方更易获得和负担得起,但读者应注意,有关口服氯胺酮的文献很少,仍有许多领域需要更多的研究,特别是与药代动力学、生理效应、滥用潜力和减轻非法使用的策略以及与其他给药途径的不良反应和疗效相关的问题。在高质量的研究结果可用之前,必须将口服氯胺酮用于治疗抑郁症视为实验性治疗。